Jan Medical

Jan Medical, founded in 2003 by serial entrepreneur Dr. Paul Lovoi, is a medical technology company focused on developing non-invasive systems for diagnosing and monitoring abnormal neurological conditions. The inspiration for the company stemmed from a personal tragedy in Dr. Lovoi's life; his wife, Jan, suffered a fatal subarachnoid hemorrhagic stroke, motivating him to find a better, less invasive method for neurodiagnostics. With a Ph.D. in physics and extensive experience in Silicon Valley startups, Dr. Lovoi applied principles from submarine signal processing to brain monitoring, leading to the development of the company's core technology.

The company operates in the medical device market, specifically targeting healthcare professionals in hospital, athletic, and military settings. Jan Medical's business revolves around the development and eventual commercialization of its proprietary diagnostic tools, with revenue streams expected from the sale of these devices. The company has secured significant funding to support its research, clinical trials, and regulatory approval processes. Over three rounds, it raised a total of $11M, with a notable Series C funding of $7.5 million in January 2016 led by medical technology firm Brainlab. This strategic partnership also provides Jan Medical with resources for clinical research, regulatory filings, and commercialization activities.

Jan Medical's primary product is the BrainPulse™ system (formerly known as Nautilus NeuroWave), a portable, non-invasive brain-sensing device. The system comprises a headset equipped with six accelerometers and a heart rate sensor, a data collector, and a computer with a touchscreen tablet interface. It functions by using the heart's cardiac output to measure the pulsatile motion of the brain, allowing for the detection of changes in vasculature and brain tissue conditions. This technology is designed to serve as a rapid diagnostic aid for conditions such as ischemic stroke, concussion, and cerebral vasospasm, with a typical recording taking only three to five minutes. The BrainPulse has received de novo clearance from the FDA as a class II device for cranial motion measurement, and the company is actively pursuing further FDA approvals for specific diagnostic indications.

Keywords: medical devices, neurodiagnostics, brain sensing, stroke detection, concussion diagnosis, cranial motion measurement, non-invasive diagnostics, accelerometry, Paul Lovoi, BrainPulse, vasospasm monitoring, cerebrovascular disease, neurological conditions, medical technology, Brainlab, portable medical device, healthcare technology, clinical trials, FDA clearance, neurocritical care